Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PROC | P04070 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119014 | 0.89 | F10 (0.72) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL7118364 | 0.84 | RAB9A (0.47) | F10RAB9AKMT2ATDP1L3MBTL1 | |
| SCHEMBL7123485 | 0.73 | F10 (1.00) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL7129110 | 0.70 | F10 (0.59) | F10ALOX5APFEN1 | |
| SCHEMBL7118369 | 0.68 | RAB9A (0.41) | RAB9AKMT2ATDP1L3MBTL1 | |
| SCHEMBL6303558 | 0.67 | F10 (0.84) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL2206387 | 0.67 | RAB9A (0.70) | RAB9AKMT2ATDP1L3MBTL1 | |
| SCHEMBL7122855 | 0.67 | F10 (0.71) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL6303168 | 0.67 | F10 (0.77) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL7113702 | 0.66 | F10 (1.00) | F10PRSS1PLGPROCKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002096873-A1 | ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | SERPINC1, F11, TFPI | F10 7/4885PRSS1 59/4885PLG 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.